Organogenesis Announces Plans To Expand Manufacturing Capacity With A Long-Term Lease A Biomanufacturing Facility Located At 100 Technology Way In Smithfield, Rhode Island
Organogenesis Announces Plans To Expand Manufacturing Capacity With A Long-Term Lease A Biomanufacturing Facility Located At 100 Technology Way In Smithfield, Rhode Island
Organogenesis宣佈計劃通過與位於羅德島史密斯菲爾德的100科技大道的生物製造設施簽訂長期租約來擴展製造業-半導體的產能。
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
Organogenesis Holdings Inc.（納斯達克股票代碼：ORGO）是一家領先的再生醫學公司，專注於高級傷口護理、外科和運動醫學市場產品解決方案的開發、製造和商業化，該公司宣佈計劃通過長期租賃位於羅德島史密斯菲爾德科技路100號的122,000平方英尺的最先進生物製造設施來擴大製造能力。
資訊熱榜
更新時間